"Upcycling" known molecules and targets for drug-resistant TB

• Published in: Frontiers in cellular and infection microbiology Vol. 12; p. 1029044
• Main Authors: Roubert, Christine, Fontaine, Evelyne, Upton, Anna M
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.10.2022
• Subjects: antibiotics; Antitubercular Agents - chemistry; Antitubercular Agents - pharmacology; Antitubercular Agents - therapeutic use; beta-Lactams; Cellular and Infection Microbiology; drug resistance; Ethionamide; golden age of antibiotics; Humans; phenotypic screening; Spectinomycin; target; Tuberculosis - drug therapy; Tuberculosis - microbiology; Tuberculosis, Multidrug-Resistant - drug therapy; phenotypic screening; drug resistance; antibiotics; golden age of antibiotics; target
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2022.1029044

Despite reinvigorated efforts in Tuberculosis (TB) drug discovery over the past 20 years, relatively few new drugs and candidates have emerged with clear utility against drug resistant TB. Over the same period, significant technological advances and learnings around target value have taken place. This has offered opportunities to re-assess the potential for optimization of previously discovered chemical matter against (M.tb) and for reconsideration of clinically validated targets encumbered by drug resistance. A re-assessment of discarded compounds and programs from the "golden age of antibiotics" has yielded new scaffolds and targets against TB and uncovered classes, for example beta-lactams, with previously unappreciated utility for TB. Leveraging validated classes and targets has also met with success: booster technologies and efforts to thwart efflux have improved the potential of ethionamide and spectinomycin classes. Multiple programs to rescue high value targets while avoiding cross-resistance are making progress. These attempts to make the most of known classes, drugs and targets complement efforts to discover new chemical matter against novel targets, enhancing the chances of success of discovering effective novel regimens against drug-resistant TB.